Judith V. Klimovsky, an officer of Genmab A/S, filed a Form 144 notice of proposed sale on November 10, 2026, covering 1,265 shares of Genmab common stock with an aggregate market value of $704,326.70.

Key Highlights

  • Proposed seller: Judith V. Klimovsky, identified in the filing as an officer of Genmab A/S.
  • Shares to be sold: 1,265 shares of Genmab common stock, with an aggregate market value of $704,326.70, according to the filing.
  • Shares outstanding: The filing reports 64,238,408 shares of common stock outstanding.
  • Approximate sale date: November 10, 2026, to be executed through Fidelity Brokerage Services LLC, 245 Summer Street, Boston, MA 02110.
  • Acquisition history: The shares were acquired via stock awards from the issuer: 365 shares on January 6, 2021, and 900 shares on January 2, 2023, both listed as compensation.
  • Prior sales: The filing reports nothing to report for securities sold during the past three months.

Klimovsky Proposes Rule 144 Sale of Genmab Common Stock

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Judith V. Klimovsky, an officer of Genmab A/S (SEC File Number 001-38976), provided notice of a proposed sale of 1,265 shares of Genmab common stock. The filing lists an aggregate market value of $704,326.70 for the shares to be sold, with the approximate date of sale noted as November 10, 2026. The securities exchange is listed as "Other" in the filing.

The filing discloses that the shares to be sold were acquired through two separate stock award transactions directly from the issuer. A total of 365 shares were acquired on January 6, 2021, and 900 shares were acquired on January 2, 2023, with both transactions described as compensation. The filing designates Fidelity Brokerage Services LLC as the broker through which the proposed sale is to be conducted, and the notice was signed by Christian Nasser as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Judith Klimovsky.

The filing states that Klimovsky "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." No securities of the issuer were reported as sold by Klimovsky during the three months preceding this notice. The total shares of Genmab common stock outstanding are reported in the filing as 64,238,408.

What Was Disclosed

Genmab A/S officer Judith V. Klimovsky filed a Form 144 on November 10, 2026, proposing to sell 1,265 shares of company common stock valued at $704,326.70, originally acquired as stock award compensation in 2021 and 2023.